Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
A phase II trial to evaluate the efficacy and safety of combination bendamustine and
rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. It is
hypothesized that the BR combination will produce at least a 70% overall response rate.